Opus Genetics, Inc. (IRD) Tops Q2 EPS by 7c

Opus Genetics, Inc. (NASDAQ: IRD) reported Q2 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $2.88 million versus the consensus estimate of $4.04 million.

For earnings history and earnings-related data on Opus Genetics, Inc. (IRD) click here.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• Opus Genetics (IRD) Reiterated at Overweight by Cantor Fitzgerald on Positive Update
• Men’s Wearhouse owner Tailored Brands, bankrupt in 2020, files for IPO